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INTRODUCTION

3

4

Arrhythmogenic right ventricular dysplasia (ARVD) and cardiac sarcoidosis (CS) are uncommon causes of VA and increase the
1,2
risk for sudden cardiac death. Both diagnoses are far distinct from each other, but they can be confused if a diagnosis is
made and alternative diagnoses are not thoroughly considered. We present the case of a 66 year-old male who presented to
our hospital in monomorphic ventricular tachycardia due to CS mistaken as ARVD.

CASE REPORT

Since the patient had known pulmonary nodules, cardiac sarcoidosis was still in our differential
diagnosis. Therefore, we obtained a fluorodeoxyglucose (FDG)-positron emission tomography (PET)
computer tomography (CT), which noted uptake within multiple, patchy parenchymal pulmonary
nodules with concurrent, nearly diffuse left ventricular and patchy right ventricular myocardial
uptake. Findings are consistent with cardiac sarcoidosis, so steroids were initiated. To monitor
response on steroids, a repeat FDG-PET CT was performed. It was notable for persistent cardiac
uptake with improving pulmonary uptake. Given his refractory disease and ICD shock, 500mg
twice daily of mycophenolate was added to his 40mg of prednisone daily.
On follow up FDG-PET CT imaging, the patient demonstrated drastic improvement in FDG uptake
within the pulmonary parenchyma, as well as left and right ventricular myocardium (Figure 3b and
Supplemental Figure 2b). Unfortunately, despite the improvement in active inflammation within
the myocardium, the patient had recurrence of his VA requiring multiple shocks within 2 weeks of
the scan requiring hospitalization. This event was attributed to scar and he underwent successful
ablation. The patient was continued on 2g per day of mycophenolate and prednisone. With 3
months of follow up there has been no VA recurrence.

Initial treatment is similar for all causes of VAs, but long-term
management of the underlying cause is crucial. First, ischemia should
be evaluated, but then other etiologies of VAs, including channelopathies,
congenital heart disease, cardiomyopathies (such as hypertrophic
cardiomyopathy), drugs, electrolyte imbalance, and infiltrative diseases
3
should then be considered. In this case, FDG PET CT was used to
monitor therapy and assist in the diagnosis CS.
CS is a rare but important cause of VA and should be pursued when the
etiology of a VA is unclear. As demonstrated in this case and prior reports
in the literature, treatable infiltrative disorders can mimic ARVD and
should be ruled out with further imaging with cardiac MRI or FDG-PET CT.

A 66 year-old white male presented to our Emergency Department (ED) with abrupt onset of
dyspnea, palpitations and lightheadedness. In the ED, he was found to be in monomorphic
ventricular tachycardia he had electric cardioversion, which resulted in normal sinus rhythm.
Initial laboratory workup came back normal and cardiac catheterization ruled out ischemia.
However, on initial ECG he was noted to have an epsilon wave in V1, a QRS of 140 and T-wave
inversions in V1-V5. Subsequently, an echocardiogram showed preserved left ventricular
function, no valvular heart disease but a markedly dilated and severely reduced right ventricle
systolic function.The patient was treated with intravenous/oral amiodarone and an implantable
cardioverter defibrillator (ICD) for secondary prevention of VAs.

CONCLUSION
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Figure 1: Initial ECG tracing notable for an epsilon wave in V1, a QRS
of 140 and T-wave inversions in V1-V5, all consistent with the diagnosis
of ARVD.

Figure 2: The four-chamber view with color Doppler image
shows the marked dilatation of the right atrial and ventricular
enlargement. We also noted tricuspid annular dilation with
secondary, moderate tricuspid regurgitation.
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Figure 3: The patient shows reduced tricuspid annulus planar
systolic excursion (TAPSE) of 1.6 cm. This is consistent with reduced
systolic function of the right ventricle.
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Figure 4a and 4b: Transverse FDG-PET CT images demonstrating
nearly complete resolution of FDG uptake within the right and left
ventricular myocardium after mycophenolate therapy was initiated.

